Loading…
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $172M | $-252M | $-285M | $-323M | -441.6% | 627.8% | - |
| 2024 | $24M | $-314M | $-319M | $-275M | -110.6% | - | - |
| 2023 | $0M | $-209M | $-209M | $-161M | -37.8% | - | - |
| 2022 | $0M | $-146M | $-149M | $-134M | -31.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 23.68 | 172.35 |
| Cost Of Revenue | 0 | 0 | 0.83 | 6.97 |
| Gross Profit | 0 | 0 | 22.85 | 165.38 |
| Operating Expense | 151.76 | 229.95 | 362.53 | 438.47 |
| Operating Income | -151.76 | -229.95 | -339.67 | -273.08 |
| EBITDA | -146.17 | -209.14 | -313.82 | -251.63 |
| EBIT | -146.20 | -209.15 | -313.83 | -251.64 |
| Pretax Income | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income Common Stockholders | -149.34 | -209.36 | -318.76 | -285.42 |
| Total Expenses | 151.76 | 229.95 | 363.35 | 445.44 |
| Interest Expense | 3.14 | 0.21 | 4.93 | 33.78 |
| Interest Income | 5.87 | 21.16 | 26.09 | 22.73 |
| Research And Development | 118.50 | 163.03 | 241.65 | 258.78 |
| Selling General And Administration | 33.26 | 66.92 | 120.88 | 179.68 |
| Normalized EBITDA | -146.17 | -209.14 | -313.82 | -251.63 |
| Normalized Income | -149.34 | -209.36 | -318.76 | -285.42 |
| Basic EPS | -2.46 | -2.98 | -3.72 | -3.29 |
| Diluted EPS | -2.46 | -2.98 | -3.72 | -3.29 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -149.34 | -209.36 | -318.76 | -285.42 |
| Reconciled Depreciation | 0.03 | 0.01 | 0.01 | 0.01 |
| Reconciled Cost Of Revenue | 0 | 0 | 0.83 | 6.97 |
| Net Interest Income | 2.73 | 20.95 | 21.16 | -11.05 |
| Net Income From Continuing And Discontinued Operation | -149.34 | -209.36 | -318.76 | -285.42 |
| Total Operating Income As Reported | -151.76 | -229.95 | -339.67 | -273.08 |
| Diluted Average Shares | 60.76 | 70.37 | 85.62 | 86.63 |
| Basic Average Shares | 60.76 | 70.37 | 85.62 | 86.63 |
| Diluted NI Availto Com Stockholders | -149.34 | -209.36 | -318.76 | -285.42 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income Continuous Operations | -149.34 | -209.36 | -318.76 | -285.42 |
| Other Income Expense | -0.32 | -0.36 | -0.25 | -1.28 |
| Other Non Operating Income Expenses | -0.32 | -0.36 | -0.25 | -1.28 |
| Net Non Operating Interest Income Expense | 2.73 | 20.95 | 21.16 | -11.05 |
| Interest Expense Non Operating | 3.14 | 0.21 | 4.93 | 33.78 |
| Interest Income Non Operating | 5.87 | 21.16 | 26.09 | 22.73 |
| General And Administrative Expense | 33.26 | 66.92 | 120.88 | 179.68 |
| Other Gand A | 33.26 | 27.22 | 50.89 | 76.94 |
| Salaries And Wages | 0 | 39.70 | 69.98 | 102.74 |
| Operating Revenue | 0 | 0 | 23.68 | 172.35 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc.this co. | SNDX | $1.8B | - | 27.92 | -441.6% | -6.40 |
| GeneDx Holdings Corp. | WGS | $1.8B | - | 5.97 | -6.8% | 141.02 |
| Inhibrx Biosciences, Inc. | INBX | $1.8B | - | 227.77 | -1752.2% | -13.63 |
| Surgery Partners, Inc. | SGRY | $1.8B | - | 1.04 | -2.2% | 11.28 |
| AnaptysBio, Inc. | ANAB | $1.8B |
| - |
| 46.94 |
| -35.6% |
| 36.55 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Peer Median | - | 11.23 | 6.60 | -39.8% | 11.28 | |